Amrutanjan Health Care Limited

rs,

i 400 051 ISIN: INE098F01031 BSE Limited Department of Corporate Services 1st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Symbol : AMRUTANJAN- ISIN: INE098F01031 Scrip Code: 590006- ISIN:

6%

Growth FY ‘25 Brand Electro+ Growth FY ‘25 Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and

4%

wth FY ‘25 Brand Electro+ Growth FY ‘25 Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Yea

16%

FY ‘25 Brand Electro+ Growth FY ‘25 Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Year End

14%

ro+ Growth FY ‘25 Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Year Ended 31st March 2025

18%

Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Year Ended 31st March 2025 5 Segment Performa

10%

tegory Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Year Ended 31st March 2025 5 Segment Performance: OTC Head

0.8%

and Amrutanjan) Congestion (Brand Relief) Category Volume Growth is back: 6%* (MAT March 25) Vs. 0.8% MAT March 24 Amrutanjan’s Value Growth was better than the Key Competition Internal Growth Driv

20%

Value Growth was better than the Key Competition Internal Growth Drivers: Small SKUs (1ml & 4ml) 20% is 19.6%* Amrutanjan’s Volume Growth (MAT March 25) Vs. 10.1 % during previous year Led by dist

19.6%

owth was better than the Key Competition Internal Growth Drivers: Small SKUs (1ml & 4ml) 20% is 19.6%* Amrutanjan’s Volume Growth (MAT March 25) Vs. 10.1 % during previous year Led by distribution g

10.1 %

owth Drivers: Small SKUs (1ml & 4ml) 20% is 19.6%* Amrutanjan’s Volume Growth (MAT March 25) Vs. 10.1 % during previous year Led by distribution growth and brand pull Internal Growth Drivers: All-round

40%

nal Growth Drivers: All-round Growth Internal Growth Drivers: Relief Inhaler Relief Mint 14% 40% Maha Strong 12% Head Roll On 7% Back Pain Roll On 18% Increased media spends (TV+Digital

“Drive to protect users from cyber threats and email fraud, improving the legitimacy of delivered using DKIM,SPF & DMARC Investor Presentation | Quarter and Year Ended 31st March 2025 17 Financials Investor Presentation | Quarter and Year Ended 31st March 2025 18 Financials – Q4 FY25 (Rs.”

“Comfy 117.24 108.37 Q4 FY25 Q4 FY24 Growth: 8.18% Net Sales - Comfy 34.46 30.27 Q4 FY25 Q4 FY24 Growth: 13.84% Sales Growth – OTC Incl.”

“G+,-./+ 1#OP$Q B=>C+a ,,,,,,, ######### ,,,,,,, =@>/A 97:; =B>@c B?>c+a Investor Presentation | Quarter and Year Ended 31st March 2025 20 Financials – Q4 FY25 (Rs.”

“in Crores) Net Sales 451.82 421.23 69.13 61.95 Profit Before Tax Profit After Tax 50.83 44.97 FY25 FY24 FY25 FY24 FY25 FY24 Growth: 7.26% Growth: 11.59% Growth: 13.03% Sales Growth (Gross Sales): !"#$%&'("#F P4R4S'478#097:;4#"$%0SF !"##A%ACD(")ACG")+DI-.AL"M"-N" !"##A%ARST8AL"M"-N" R==A%A>?@ARAAOOBACACD(")A+=aN#DE"-D# R==A%AeAI /#0FF7C"(4F G+,- 7777777 AAAAAAAAAAA AAAAAAAAAAA AAAAAAAAA AAAAAAAAA 7777777 .-Y=>, OP4O OP49 O9PF: 49Pgg -a>=,E G+,.”

“OPOO :P;< OBPOd 4<PB; .@a=E@ 777777 AAAAAAAAA AAAAAAAAA AAAAAAA AAAAAAA 777777 /#01$O @=,AB @=E,B Investor Presentation | Quarter and Year Ended 31st March 2025 22 Expenses – FY25 (Rs.”

“in Crores) Employee Benefit Expenses 59.10 47.69 FY25 FY24 Increase: 23.93% Advertisement & Selling Expenses 56.11 52.42 Other Expenses 55.20 57.48 FY25 FY24 FY25 FY24 Increase: 7.04% Decrease: 3.97% Investor Presentation | Quarter and Year Ended 31st March 2025 23 Financials – FY25 – OTC Division (Rs.”

“Comfy 413.99 380.39 FY25 FY24 Growth: 8.83% Net Sales - Comfy 123.96 105.26 FY25 FY24 Growth: 17.77% Sales Growth – OTC Incl.”

“• Advertisement spend for FY25 is at Rs.”

“Investor Presentation | Quarter and Year Ended 31st March 2025 24 Financials – FY25 – Beverage Division (Rs.”

“in Crores) Net Sales - Beverages 36.43 39.98 FY25 FY24 Net Sales - Electro Plus 32.47 31.56 FY25 FY24 Growth: 2.88% Sales Growth - Beverages (Gross): !"#$%&'("#F /010O'0P4#RSP780#"$%ROF !""#A#%&D#!(#))G#+#I-./0#N"O34-5/S-4 !""#A#;(< >#RFFP?"(0F G+,- PPPPPPPPP ########### ########### PPPPPPPPP 9:;.9 T899 T8=> .-;=, G+,.”

Internal Growth Drivers

3

Notes

2

Management

1

Congestion

1

Rehydration

1

Rehydration

41.4 Crs Investor Presentation | Quarter and Year Ended 31st March 2025 Brand Electro+ Note: Nos. given are Gross Sales 4 FY 24-25: Growth driven by all Categories Pain Management Congestion Women’s Hygiene Rehydration Brand Amrutanjan Growth FY ‘25 Brand Relief Growth FY ‘25 Brand Comfy Growth FY ‘25 Brand Electro+ Growth FY ‘25 Overall Pain Category Head Category Body Category 6% 4% 16% Relief Range 14% Overall Comfy 18% Electro+ 10% Investor Presentation | Quarter and Year Ended 31st March 2025 5 Segment Performance: OTC Head Category (Brand Amrutanjan) Body Category (Brand Amrutanjan) Congestion (Brand Relief) Category Volume Growth is back: 6%* (MAT March 25) Vs. 0.8% MAT March 24 Amrutanjan’s Value Growth was better than the Key Competition

Internal Growth Drivers

Small SKUs (1ml & 4ml) 20% is 19.6%* Amrutanjan’s Volume Growth (MAT March 25) Vs. 10.1 % during previous year Led by distribution growth and brand pull Internal Growth Drivers: All-round Growth

Internal Growth Drivers

Relief Inhaler Relief Mint 14% 40% Maha Strong 12% Head Roll On 7% Back Pain Roll On 18% Increased media spends (TV+Digital) resulted in doubling the Per Dealer Offtake (PDO) value growth: 8.5%* in MAT March 25 Vs 4% YA Investor Presentation | Quarter and Year Ended 31st March 2025 * IQVIA Sprays 24% 6 Segment Performance: Women’s Hygiene and Rehydration Women’s Hygiene (Brand Comfy) Rehydration (Brand Electro+) Fastest growing category in Amrutanjan’s portfolio Growth led by Orange variant New Products launched in Q4 FY ‘25, contributed to 9% of the overall Electro+ brand

Internal Growth Drivers

Comfy XL Variant 59% Comfy Slimfit ~2X Growth Increase in XL Variant’s contribution to Overall Comfy: 31% in FY ‘25 Vs 23% YA Women’s Hygiene Category contributed to 1/4th of AHCL in FY ‘25 with an increase of 200 Basis points over the previous year Investor Presentation | Quarter and Year Ended 31st March 2025 7 Complete Rehydration Portfolio with new launches New SKUs and Variants to address diverse consumer needs APPLE ORANGE APPLE ORANGE ORANGE Low Unit Pack to make Electro+ accessible W.H.O. ORS (Liquid) W.H.O. ORS (Powder) Investor Presentation | Quarter and Year Ended 31st March 2025 8 Marketing Interventions: Head and Body High Impact Properties: TV High Impact Properties: On-ground • Objective: To build Awareness and Consideration • Markets: Key States of AHCL’s Pain Category • Objective: To build Awareness and Consideration • Markets: Key States of AHCL’s Pain Category Big Boss Kannada Reality Show in AP TG Outlet Branding Metro Branding Investor Presentation | Quarter and Ye

Notes

• Majority of raw material & packing material prices are lower than FY24. Menthol Crystal price is marginally lower than FY24. • Advertisement spend for FY25 is at Rs. 33.92 Cr against Rs. 30.04 Cr for FY24. Advertisement spend for Comfy is at Rs. 8.03 Cr for FY25 against Rs. 6.47 Cr for FY24. Investor Presentation | Quarter and Year Ended 31st March 2025 24 Financials – FY25 – Beverage Division (Rs. in Crores) Net Sales - Beverages 36.43 39.98 FY25 FY24 Net Sales - Electro Plus 32.47 31.56 FY25 FY24 Growth: 2.88% Sales Growth - Beverages (Gross): !"#$%&'("#F /010O'0P4#RSP780#"$%ROF !""#A#%&D#!(#))G#+#I-./0#N"O34-5/S-4 !""#A#;(< >#RFFP?"(0F G+,- PPPPPPPPP ########### ########### PPPPPPPPP 9:;.9 T899 T8=> .-;=, G+,. PPPPPPP ######### ######### PPPPPPP 9Y;Y= :8:: G8?T .@;,. Sales Growth - Electro Plus (Gross): !"#$%&'("#F G+,- G+,. /#01$O P4R4S'478#097:;4#"$%0SF !""#A#%&D#!(#))G#+#I-./0#N"O34-5/S-4 !""#A#;(< /#0FF7C"(4F 777777777 ########### ########### 777777777 Y,=.> T899 T8:: .?=Y- 77

Notes

• • • Raw Material & Packing material prices are higher when compared to FY24. Advertisement spend is at Rs. 5.89 Cr for FY25 against Rs. 5.99 Cr for FY24. Business is continuing with cash & carry model for Fruitnik. Investor Presentation | Quarter and Year Ended 31st March 2025 25 Management Commentary Investor Presentation | Quarter and Year Ended 31st March 2025 26 Management Commentary 1. The Pain management category’s revival in q3 of this fiscal year continued into q4 with growth of 7% 2. The top end and bottom end of the SKUs witnessed growth this year-Roll on, large packs and LUP 1. The 8ml SKU that contributes to 40% of total category sales remains flat for the year but witnessed revival in H2 2. Per Kantar, the topical ointments for headache have a house hold penetration of around 50%. 1. We feel this is low for a category that has been in existence for more than 125 years 2. LUP packs’ growth is a testament to penetration increase both from demand and supply side 3. The low